Tecnovigilancia in Colombia: Adverse Event Reporting Requirements for Devices

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Resolución 4816 de 2008 established the Programa Nacional de Tecnovigilancia, Colombia’s national device vigilance program. The provision that matters most to Chinese manufacturers is this: serious adverse events must be reported to INVIMA within 72 hours of becoming aware. The clock starts on awareness — not on the occurrence of the event, and not on confirmation of causality. In addition, periodic reports are submitted quarterly, and recalls are executed under INVIMA directives.

GRZAN’s judgment is that the hard part of the 72-hour line is not the deadline itself but the information transfer chain. Foreign manufacturers are usually not the first to become aware: the earliest holders of the information are the local Colombian importer, the healthcare facility using the product, or the local legal representative (apoderado / representante legal). If no transfer deadlines have been agreed among these parties in advance, the 72 hours will be half consumed in internal routing. The center of gravity of vigilance system building is therefore not inside China, but at the information interface on the Colombian end. Building that interface is not a one-off task: it must be written into the POA, reflected in written agreements, and rehearsed before any event occurs.

2. Legal basis

RegulationNumberPublication dateProvisions
Resolución 4816 de 2008 (national device vigilance program)Resolución 4816 de 20082008Report serious adverse events within 72 hours of awareness; periodic reports submitted quarterly; recalls executed under INVIMA directives
Decreto 4725 de 2005 (registration, marketing authorization and health surveillance regime for medical devices)DECRETO 4725 DE 26 DE DICIEMBRE DE 2005December 26, 2005Art. 1 (scope), Art. 3 (definitions of titular / fabricante / importador), Art. 29 (POA), Art. 40 (implant card)
Decreto 582 de 2017 (amending Decreto 4725 de 2005)Decreto 0582 de 2017April 4, 2017Ex-post verification and suspension / cancellation rules
Resolución 1405 de 2022 (semantic standard and UDI-DI)Resolución 1405 de 2022August 8, 2022Three-category attribute provisions (basic attributes include UDI-DI and GMDN)
Ley 962 de 2005 (anti-bureaucracy law)Ley 962 de 20052005Article 57 (follow-up control within 15 days after issuance)

3. Expert insights

1. The clock starts on awareness, and the aware party is often not in China

This formulation ties the obligation to the moment the information arrives, not to the date of the event or the completion of an investigation. For a foreign manufacturer it means two things: you must designate a natural person or entity inside Colombia that can immediately start the reporting action, and you must agree with that party on the maximum internal transfer time. When GRZAN helps clients build a vigilance system, it typically splits the 72 hours into two segments — no more than 24 hours for transmission from abroad to the local party, leaving 48 hours locally for verification and form filling. The purpose of this split is to convert uncontrollable internal communication time into an auditable service level.

2. Quarterly periodic reporting is a standing duty, not something to do only when something happens

The absence of serious adverse events does not remove the reporting obligation. The function of the periodic report is to bring even a zero report within the regulator’s view — it is how the authority judges whether a company is genuinely operating a vigilance system. The typical failure pattern GRZAN observes is a company that pours all its energy into sales after obtaining the certificate, leaves the vigilance system blank, and is only found out during a spot check or a follow-up control. The missing quarterly report is itself a verifiable compliance gap.

3. UDI-DI determines tracing precision, and vigilance records will be examined

The direct value of the UDI-DI required by Resolución 1405 de 2022 for vigilance lies in tracing precision: without semantic coding, a report can only describe the product name and model, and the scope of any trace-back is forced wide; once coding is complete, a report can be anchored to a specific device identifier, and the scope of recalls and field handling narrows significantly. At the same time, the follow-up control under Article 57 of Ley 962 de 2005 and the ex-post verification under Decreto 582 de 2017 turn the vigilance ledger from an internal archive into examinable evidence. GRZAN recommends maintaining the vigilance ledger separately from the registration ledger while keeping the two cross-referenceable.

4. Practical recommendations

  1. Chinese manufacturers: designate a vigilance responsible person in Colombia and define their vigilance authority in the POA (Art. 29).
  2. Chinese manufacturers: sign written information transfer agreements with the local legal representative and importers, setting the maximum time to reach the reporting responsible person (24 hours recommended).
  3. Vigilance responsible person: maintain a 72-hour countdown ledger with the starting point recorded as the moment of awareness, and preserve evidence of how awareness was obtained.
  4. Vigilance responsible person: submit periodic reports quarterly, including zero reports when there are no events, and retain submission receipts.
  5. Quality and compliance leads: implement the patient implant card system for implantable devices under Art. 40, making implant patients traceable.
  6. Regulatory affairs leads: after completing semantic reporting, add UDI-DI and GMDN terms as fields in the vigilance ledger.

5. Verification checklist

  • □ A vigilance responsible person has been designated within Colombia, with authority defined in the POA
  • □ Written transfer deadlines have been agreed with the local legal representative and importers (24 hours recommended)
  • □ A 72-hour countdown ledger exists, with the moment of awareness as the starting point
  • □ A quarterly periodic reporting mechanism is in place, including a zero-report process and receipt retention
  • □ Implantable devices have the patient implant card system implemented under Art. 40
  • □ UDI-DI and GMDN terms have been added as fields in the vigilance ledger

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN delivers post-market compliance support for the Colombian market: technovigilance system design and adverse event reporting to INVIMA, quarterly periodic reporting, recall execution under INVIMA directives, and readiness for follow-up controls and inspections. If you need to build or audit a Colombia vigilance system, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail